Futibatinib
ATC L01EN04 · 7 markets · 10 records
AU 3 records · 2 strengths
- 4 mgtabletLYTGOBILYTGOBI futibatinib 4 mg tablet blister pack
Records without a stated strength · 1 LYTGOBI
US 2 records · 2 strengths
GB 1 records · 1 strengths
- 4 mgtabletLYTGOBI
SG 1 records · 1 strengths
- 4 mgtabletLYTGOBI
ES 1 records · 1 strengths
- 4 mgtabletLYTGOBI
HK 1 records · 1 strengths
Records without a stated strength · 1 LYTGOBI
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 LYTGOBI
| Strength / form / release | US | GB | AU | SG | ES | HK | EU |
|---|---|---|---|---|---|---|---|
| 4 mg tablet | LYTGOBI | LYTGOBI | LYTGOBI LYTGOBI futibatinib 4 mg tablet blister pack | LYTGOBI | LYTGOBI | ||
| 16 mg tablet | LYTGOBI | ||||||
unknown | LYTGOBI | LYTGOBI | LYTGOBI |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.